Several analysts have recently updated their ratings and price targets for Fresenius Medical Care AG (NYSE: FMS):

  • 9/21/2016 – Fresenius Medical Care AG had its “buy” rating reaffirmed by analysts at Goldman Sachs Group Inc..
  • 9/16/2016 – Fresenius Medical Care AG had its “neutral” rating reaffirmed by analysts at DZ Bank AG.
  • 9/13/2016 – Fresenius Medical Care AG had its “buy” rating reaffirmed by analysts at Goldman Sachs Group Inc..
  • 9/6/2016 – Fresenius Medical Care AG was upgraded by analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating.
  • 8/9/2016 – Fresenius Medical Care AG had its “buy” rating reaffirmed by analysts at Berenberg Bank.
  • 8/4/2016 – Fresenius Medical Care AG had its “neutral” rating reaffirmed by analysts at DZ Bank AG.

Fresenius Medical Care AG (NYSE:FMS) traded up 0.73% during midday trading on Wednesday, hitting $44.35. The company had a trading volume of 144,121 shares. The stock has a market cap of $27.12 billion, a price-to-earnings ratio of 24.58 and a beta of 0.53. Fresenius Medical Care AG has a 12-month low of $38.11 and a 12-month high of $47.52. The company’s 50 day moving average is $45.27 and its 200 day moving average is $43.75.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/fresenius-medical-care-ag-fms-investment-analysts-weekly-ratings-updates.html

Fresenius Medical Care AG (NYSE:FMS) last announced its earnings results on Tuesday, August 2nd. The company reported $0.96 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.92 by $0.04. Fresenius Medical Care AG had a return on equity of 9.66% and a net margin of 6.40%. The firm had revenue of $4.42 billion for the quarter, compared to analysts’ expectations of $4.54 billion. On average, equities analysts anticipate that Fresenius Medical Care AG will post $2.01 EPS for the current fiscal year.

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

5 Day Chart for NYSE:FMS

Receive News & Ratings for Fresenius Medical Care AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG and related companies with MarketBeat.com's FREE daily email newsletter.